Global Talazoparib Market Overview:
Talazoparib, sold under the brand name Talzenna, is an orally available inhibitor of the poly-ADP-ribose polymerase (PARP) developed by Pfizer to treat advanced breast cancer with BRCA mutations in the germline. Talazoparib is similar to the first PARP inhibitor in its class, olaparib. It was approved in October 2018 in the United States and in June 2019 in the European Union for BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer in the germline. The most serious side effects in studies concerned the hematopoietic system and included anemia (low red blood cell count), neutropenia (low neutrophil count) and thrombocytopenia (low platelet count). Serious forms of these diseases (grade 3 to 4) occurred in 39%, 21%, and 15% of the patients. Other side effects such as headache, nausea, hair loss, and fatigue were mostly mild. Talazoparib acts as an inhibitor of poly-ADP ribose polymerase (PARP), which aids in the repair of single-stranded DNA. Cells with BRCA1 / 2 mutations are susceptible to the cytotoxic effects of PARP inhibitors due to the accumulation of DNA damage. Talazoparib is believed to be more potent than olaparib due to the additional mechanism of action known as PARP trapping. PARP trapping is the mechanism of action in which the PARP molecule is trapped on the DNA, which impairs the ability of the cell to replicate. Talazoparib is ~ 100 times more efficient than olaparib in trapping PARP. However, this increased efficacy may not lead directly to clinical efficacy as many other factors need to be considered. Some of the players profiled in the study are Pfizer (United States).
On the basis of geography, the market of Talazoparib has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Disease Type, the sub-segment i.e. Treat Prostate Cancer will boost the Talazoparib market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Online will boost the Talazoparib market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Market Growth Drivers
- Growing Geriatric Population in Major Economies
- Increasing No of Cancer Patients Worldwide
- Growing Usage because of its Cost-Effectiveness as Compare to Chemo Therapy
- Increasing Healthcare Spending and Demand for Drug Therapy
- Stringent Government Rules and Regulation
- Side Effects Due to Talazoparib Drug
- R&D and Product Innovation
- Potential Growth From Emerging Countries
- Availability of Substitutes
The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to avail of competitive advantage through combined collaborations.
Target Audience:Manufacturers of Talazoparib, Suppliers and Distributors of Talazoparib, Raw Material Suppliers, Commercial Research & Development (R&D) Institutions, Government Organizations, Research Organizations and Healthcare Industry
Major Objectives Focused through this Study To define, describe, and forecast the Global Talazoparib market on the basis of product [0.25mg Capsules and 1mg Capsules] , application [Hospital, Drug Center and Clinic], key regions and end user
To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
To provide market size for various segments of the Talazoparib market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
To strategically profile the key players and analyzing their market shares and core competencies in the Talazoparib industry
To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market
Available Customization: Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are .
** Confirmation on availability of data would be informed prior purchase
While framing the research framework, major and emerging players operating in the Talazoparib market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.